Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: A pilot study

Epileptic Disorders

Volumn 14, Issue 4, 2012, Pages 388-397

  Maschio, Marta ^a   Dinapoli, Loredana ^a   Sperati, Francesca ^a   Pace, Andrea ^a   Fabi, Alessandra ^a   Vidiri, Antonello ^a   Pompili, Alfredo ^a   Carapella, Carmine Maria ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anxiety; Brain tumor; Efficacy; Epilepsy; Pregabalin; Quality of life

Indexed keywords

BEVACIZUMAB; CLOBAZAM; ETIRACETAM; FOTEMUSTINE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PREGABALIN; TEMOZOLOMIDE; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADULT; AGED; ANXIETY; ARTICLE; ASTROCYTOMA; BRAIN METASTASIS; BRAIN SURGERY; BRAIN TUMOR RELATED EPILEPSY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DISEASE CONTROL; DISEASE EXACERBATION; DISTRESS SYNDROME; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EPILEPSY; EYE IRRITATION; FEMALE; GLIOBLASTOMA; GLIOSIS; HUMAN; MALE; MENINGIOMA; OLIGODENDROGLIOMA; OPEN STUDY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOSURGERY; SOCIAL LIFE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTICONVULSANTS; ANXIETY; BENZODIAZEPINES; BRAIN NEOPLASMS; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PHENOBARBITAL; PILOT PROJECTS; PIRACETAM; QUALITY OF LIFE; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID; YOUNG ADULT;

EID: 84874642911     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2012.0542     Document Type: Article

References (41)

1. Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol 1998;9:549-57.
2. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007;52:333-46.
3. Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007;7:769-81.
4. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005;46:1407-13.
5. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events 2003. v4.0. http://ctep. cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev4.pdf
6. Carreño M, Maestro I, Molins A, et al. Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice. Seizure 2007;16:709-12.
7. Cramer JA, Van Hammée G; N132 Study Group. Maintenance of improvement in health-related quality of life during longterm treatment with levetiracetam. Epilepsy Behav 2003;2:118-23.
8. Folstein MF, Folstein SE, McHugh PR. Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
9. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1631-7.
10. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects. A randomized trial. Neurology 2004;62:23-7.
11. Giovagnoli AR. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumor. J Neurol Neurosurg Psychiatry 1999;67:358-63.
12. Hamilton M. The assessment of anxiety states by rating. Br J Med Psych 1959;32:50-5.
13. Karnofsky DA, Burchenal JH, Armistead GC Jr, et al. Triethylene melamine in the treatment of neoplastic disease. Arch Int Med 1951;87:477-516.
14. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602.
15. Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P glycoprotein. Neuropharmacology 2008;55:1364-75.
16. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;4:61-5.
17. Maschio M, Albani F, Baruzzi A, et al. Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 2006;80:97-100.
18. Maschio M, Dinapoli L, Zarabla A, et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 2008;86:61-70.
19. Maschio M, Dinapoli L, Vidiri A, et al. The role sideeffectsplay in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 2009a; 28:60.
20. Maschio M, Dinapoli L, Saveriano F, et al. Efficacy and tolerability of zonisamide as add-on in brain tumorrelated epilepsy: preliminary report. Acta Neurol Scand 2009b; 120:210-2.
21. Maschio M, Dinapoli L, Sperati F, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 2011a;104:205-14.
22. Maschio M, Dinapoli L, Mingoia M, et al. Lacosamide as addon in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol 2011b;258:2100-4.
23. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008;193:389-94.
24. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumour patients. J Neurooncol 2005;78:99-102.
25. Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia 2006;47:1237-8.
26. Novy J, Stupp R, Rossetti AO. Pregabalin in patients with primary brain tumours and seizures: a preliminary observation. Clin Neurol Neurosurg 2009;111:171-3.
27. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and nonenzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005;72:255-60.
28. Owen RT. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today 2007;43:601-10.
29. Pace A, Vidiri A, Galiè E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003;14:1722-6.
30. Perry JR, Sawka C. Add-on gabapentin for refractory seizures in patientswithbrain tumors. Can J Neurol Sci 1996;23:128-31.
31. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2005;61:246-55.
32. Rossetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol 2010;23:603-9.
33. Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry 2007;78:342-9.
34. Stein DJ. Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder. Evid Based Ment Health 2007;10:23.
35. Striano S, Striano P, Boccella P, Noverino C, Bilo L. Tiagabine in glial tumors. Epilepsy Res 2002;49:81-5.
36. Van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007;6:421-30.
37. Vecht CJ, Van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006;67:S10-3.
38. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404-9.
39. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002;14:299-307.
40. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008;30:1385-407.
41. Zung WW. Aself-ratingdepressionscale. Arch Gen Psychiatry 1965;12:63-70.